Pexidartinib
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib
This site is for U.S. Healthcare Professionals only.
Publications
This section includes selected Daiichi Sankyo-sponsored publications.
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
T-DXd
Breast Cancer
Cost-effectiveness of trastuzumab deruxtecan in patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy
Paulissen JHJ, van Schoonhoven AV, Olin E, et al.
Adv Ther. 2025;42(1):322-333. doi: 10.1007/s12325-024-03033-2
Edoxaban
Cardiovascular - AF
Impact of diagnostic coding schemas on major bleeding risk assessment for oral anticoagulants in patients with atrial fibrillation using administrative claims data
Chien H-T, Chao T-F, Wang R, et al.
J Thromb Haemost. 2024:S1538-7836(24)00730-X. doi: 10.1016/j.jtha.2024.12.010.
Other/Multi
Lung Cancer
A podcast discussion on the intracranial efficacy of antibody-drug conjugates in patients with EGFR-mutated NSCLC with brain metastases
Johnson ML, Lin JJ, Boire A, Khandekar MJ, Yu HA
Oncol Ther. 2024. doi: 10.1007/s40487-024-00315-1.
T-DXd
Breast Cancer
Other/Multi
Trastuzumab deruxtecan with nivolumab in HER2-expressing metastatic breast or urothelial cancer: Analysis of the phase 1b DS8201-A-U105 study
Hamilton E, Galsky MD, Ochsenreither S, et al.
Clin Cancer Res. 2024. doi: 10.1158/1078-0432.CCR-24-1513. Epub ahead of print.
T-DXd
Gastric Cancer
Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)
Kawakami H, Nakanishi K, Makiyama A, et al.
Gastric Cancer. 2024. doi: 10.1007/s10120-024-01555-w. Epub ahead of print.
T-DXd
Lung Cancer
Analytical and clinical validation of the Oncomine Dx Target Test to assess HER2 mutation status in tumor tissue samples from patients with non-small cell lung cancer treated with trastuzumab deruxtecan in the DESTINY-Lung01 and DESTINY-Lung02 studies
Qi Z, Ha T, Feng W, et al.
Arch Pathol Lab Med. 2025 Jun 1;149(6):542-549. doi: 10.5858/arpa.2024-0014-OA. Epub ahead of print.
T-DXd
Breast Cancer
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
Sakai H, Tsurutani J, Ozaki Y, et al.
Ann Oncol. 2024:S0923-7534(24)03995-4. doi: 10.1016/j.annonc.2024.09.001. Epub ahead of print.
T-DXd
Breast Cancer
Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer
Bardia A, Hu X, Dent R, et al.
N Engl J Med. 2024. doi: 10.1056/NEJMoa2407086. Epub ahead of print.
T-DXd
Breast Cancer
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: A phase 3b/4 trial
Harbeck N, Ciruelos E, Jerusalem G, et al.
Nat Med. 2024. doi: 10.1038/s41591-024-03261-7. Epub ahead of print.
DataSource by Daiichi Sankyo website provides U.S.
healthcare professionals with high quality, fair balanced, evidence-based medical information.
The information provided is for education purposes only and is not intended as medical advice.
Please choose an option below